Stanford, California 94305

  • Treatment Resistant Depression

Purpose:

This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD) or BD. aiTBS is a novel application of repetitive transcranial magnetic stimulation (TMS), that induces remission in 90% of individuals with severe, treatment resistant MDD in 1-5 days.


Study summary:

Repetitive transcranial magnetic stimulation (rTMS) is an established therapy for treatment-resistant depression. The approved method for treatment is 10Hz stimulation for 40 min over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been effective in real world situations. The limitations of this approach include the duration of the treatment (approximately 40 minutes per treatment session, 5 days per week, for 4-8 weeks). Recently, the investigators have pursued modifying the treatment parameters to reduce treatment times with an accelerated treatment paradigm with great preliminary success. This study aims to further study the accelerated protocol and examine changes in neuroimaging biomarkers.


Criteria:

Inclusion Criteria: 1. Male or Female, between the ages of 18 and 80 at the time of screening. 2. Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI assessments and aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information. 3. Currently diagnosed with Major Depressive Disorder (MDD) or Bipolar Disorder type II and meets criteria for a Major Depressive Episode, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5). 4. Medical records confirming a history of moderate to severe treatment-resistance as defined by a score of 7-14 on the Maudsley Staging Method (MSM). 5. MADRS score of ≥20 at screening (Visit 1). 6. TMS naive. 7. Access to ongoing psychiatric care before and after completion of the study. 8. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study enrollment and agree to continue this regimen throughout the study period. 9. In good general health, as evidenced by medical history. 10. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation. Exclusion Criteria: 1. Pregnancy 2. Primary psychiatric condition other than MDD requiring treatment except stable co-morbid anxiety disorder 3. History of or current psychotic disorder or bipolar disorder 4. Diagnosis of Intellectual Disability or Autism Spectrum Disorder 5. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal 6. Urine screening test positive for illicit substances 7. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt within the past 90 days 8. Any history of ECT (greater than 8 sessions) without meeting responder criteria 9. Recent (during the current depressive episode) or concurrent use of rapid acting antidepressant agent (i.e., ketamine or a course of ECT) 10. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma 11. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion) 12. Contraindication to MRI (ferromagnetic metal in their body) 13. Treatment with another investigational drug or other intervention within the study period 14. Any other condition deemed by the PI to interfere with the study or increase risk to the participant


NCT ID:

NCT05144789


Primary Contact:

Principal Investigator
David Spiegel, MD
Stanford University

Romina Nejad, MSc
Phone: 650-497-3933
Email: rnejad@stanford.edu


Backup Contact:

Email: nbassano@stanford.edu
Nick Bassano, MSW
Phone: 650-736-2233


Location Contact:

Stanford, California 94305
United States

Romina Nejad, MSc
Phone: 650-497-3933
Email: rnejad@stanford.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 28, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.